Data presented at ENDO 2022 indicates low rates of hyperglycemic events were easily controlled, did not cause treatment disruption and were most often seen in patients with pre-existing diabetes A separate poster presentation examined response to TEPEZZA in patients who were mildly hypothyroid and found outc.
DUBLIN (BUSINESS WIRE) Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conference in June:Goldman Sachs 43rd Annual Global Health Care ConferenceDate: Tuesday, June 14, 2022Presentation Time: 11 a.m. ETThe conference presentation will be webcast live and m.
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conference in June: Goldman Sachs 43rd Annual Global Health Care Conference Date:
Poster presentation will share results from the Phase 2 and Phase 3 trials on blood glucose levels in patients with Thyroid Eye Disease (TED) Three-time Olympic gold medalist Gail Devers will
Data being presented at the CMSC Annual Meeting demonstrates UPLIZNA may reduce attack risk and disability among populations with genetic variables typically linked to poor treatment response